$7m market cap

$1.25 last close

OpGen is a diagnostic company focused on revolutionizing the identification and treatment of bacterial infections. The Acuitas AMR Gene Panel molecular test, in combination with the Acuitas Lighthouse bioinformatics product, detects multiple pathogens and predicts antibiotic resistance in less than three hours.

Investment summary

In September, OpGen announced a merger with Curetis, a Germany-based molecular diagnostics company with a similar focus on infectious disease. Curetis has two main business lines, the Unyvero A50 high-plex polymerase chain reaction (PCR) platform for the diagnosis of infectious disease in hospital patients and the ARES AMR database (ARESdb), which includes data on 40,000 sequenced strains with a focus on resistant pathogens. Closure is dependent on certain conditions including approval by both OpGen and Curetis shareholders, currently expected by the end of January 2020.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2017A 3.2 (15.3) (15.6) (19624.85) N/A N/A
2018A 2.9 (13.2) (13.4) (3351.27) N/A N/A
2019E 3.5 (12.3) (12.6) (642.50) N/A N/A
2020E 5.3 (15.7) (15.8) (281.16) N/A N/A
Industry outlook

It currently takes days to test a patient sample to find out if they have an infection, what they are infected with and to which drugs that infection might be susceptible. This can lead to a delay in treatment or the wrong treatment being prescribed. According to the Centers for Disease Control and Prevention, there are over two million cases of drug-resistant bacterial infections every year.

Last updated on 03/12/2019
Share price graph
Balance sheet
Forecast net cash (US$m) 5.2
Forecast gearing ratio (%) N/A
Price performance
Actual (85.7) (81.0) (96.0)
Relative* (86.3) (82.6) (96.5)
52-week high/low US$2.2/US$0.2
*% relative to local index
Key management
Evan Jones CEO
Tim Dec CFO